Glooko Inc., Gothenburg, Sweden, announced a strategic collaboration with Eli Lilly and Company, Indianapolis, Ind., for people with diabetes that use Lilly’s connected insulin pen solutions. The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the United States, via integration of Lilly’s Tempo Pen and Tempo Smart Button (currently in late-stage development) with Glooko’s platform.
Glooko’s platforms are compatible with over 95% of diabetes devices globally, and the Lilly collaboration expands upon the company’s device-agnostic model for remote patient monitoring and patient data management. This gives patients and their healthcare providers more freedom of choice for managing their care.
The Tempo Pen is an enhanced version of Lilly’s current prefilled, disposable insulin pen to which the Tempo Smart Button (pending CE mark) attaches. Through this new agreement, the Tempo Smart Button will pair with Glooko’s software to facilitate the integration of personalized healthcare data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers, and food logs. The integrated and actionable insights available in Glooko will improve the standard of diabetes care.
“Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch,” says Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes. We are excited about continuing to expand the availability of our solution and look forward to helping more people manage their diabetes through our innovative products.”
Lilly aims to receive CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button with Glooko’s platform following this certification. “We’re pleased to work alongside Glooko on our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community,” says Marie Schiller, vice president of product development for connected care and insulins at Lilly. “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses. By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection. ”
